BioCentury
ARTICLE | Strategy

Starting earlier at GSK

GSK deals in basic research

August 20, 2015 7:00 AM UTC

GlaxoSmithKline plc is extending its "buy-over-build" strategy for research with a new arm of academic outsourcing targeted at even earlier stage projects than the translational and clinical alliances it already has in place. With a pair of deals in July covering six U.K.-based academic organizations, the company is building ties in basic research that bring it back to a space it had all but abandoned.

"I think we're almost defining a new phase of interaction within the industry," said David Powell, director of the Crick-GSK open science collaboration. "What we're now doing as a company is going back into the very basic biology stage, an area that we haven't existed in for a very long time."...